Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma

Japanese Journal of Clinical Oncology

Volumn 40, Issue 5, 2010, Pages 395-403

  Chiba, Yasuyoshi ^a   Hashimoto, Naoya ^a   Tsuboi, Akihiro ^a   Oka, Yoshihiro ^a   Murao, Ayako ^a   Kinoshita, Manabu ^a   Kagawa, Naoki ^a   Oji, Yusuke ^a   Hosen, Naoki ^a   Nishida, Sumiyuki ^a   Sugiyama, Haruo ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Glioma; Temozolomide; Wilm's tumour 1; WT1 specific T cells

Indexed keywords

TEMOZOLOMIDE; WT1 PROTEIN; ALKYLATING AGENT; CANCER VACCINE; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOBLASTOMA; HUMAN; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; RADIATION RESPONSE; REGULATORY T LYMPHOCYTE; STUDENT T TEST; THERAPY EFFECT; BRAIN TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; GLIOMA; IMMUNOLOGY; JAPAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; JAPAN; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; RADIOTHERAPY, CONFORMAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; WT1 PROTEINS;

EID: 77952571447     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp196     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2002;2:45-54.
3. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001;73:177-87.
4. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90:194-204.
5. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al. Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 2004;95:822-7.
6. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164:1873-80.
7. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13 885-90.
8. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004;18:165-6.
9. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al. Phase II clinical trial of Wilms' tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108:963-71.
10. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009;8:493-9.
11. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-6.
12. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005;23: 4235-6.
13. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10:98-103.
14. Sampson JH, Aldape KD, Gilbert MR, Hassenbusch SJ, Sawaya R, Schmittling B, et al. Temozolomide as a vaccine adjuvant in GBM. J Clin Oncol 2007;25(Suppl 18):2020.
15. Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, et al. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol 2006;24(Suppl 18):2529.
16. Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 2008;26(Suppl 15):2011.
17. de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 2003;88:175-80.
18. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007;25:3485-91.
19. Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 2007;122:615-22.
20. Bassini C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in rat glioma model. Cancer Immunol Immunother 2009;58:1627-34.
21. Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, et al. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 2007;30:240-50.